1014 GMT - Haleon's earnings-per-share beat signals an turning point, Barclays analysts say in a note. The British consumer-health giant's historical lack of EPS delivery has been a key investor complaint which should ease now after its 2H topped consensus by 6%, Barclays says. "Given recent strength in Haleon's share price we could see some profit taking first thing this morning, but the robust topline and EPS delivery confirm our thesis that Haleon is establishing a track record as a steady compounder," the analysts say. Haleon's 2025 guidance is in line with expectations, but its 2H weighting comes as a surprise, they add. Shares are down 3.1% at 38.33 pounds. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 27, 2025 05:14 ET (10:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。